InMed Pharmaceuticals
Clinical-stage pharmaceutical company developing small-molecule therapeutics that target CB1/CB2 receptor pathways and a parallel cannabinoid synthesis manufacturing capability to produce bioidentical, pharmaceutical-grade rare cannabinoids. Operates preclinical and clinical programs across neurological, ophthalmic and dermatological indications and supplies high-purity rare cannabinoids for B2B customers via a manufacturing subsidiary.
Industries
Nr. of Employees
small (1-50)
InMed Pharmaceuticals
#1445 - 885 West Georgia St., Vancouver, BC, V6C 3E8, Canada
Patents
Topical formulations of cannabinoids and use thereof in the treatment of pain
US-12357604-B2
View DetailsUse of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
US-12042479-B2
View Details
Topical formulations of cannabinoids and use thereof in the treatment of pain
US-12357604-B2
View DetailsUse of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
US-12042479-B2
View DetailsProducts
Pipeline of small-molecule therapeutics targeting CB1/CB2 pathways
Clinical- and preclinical-stage small-molecule programs focused on neurological (including Alzheimer’s disease), ophthalmic (dry age-related macular degeneration) and dermatological (epidermolysis bullosa, glaucoma) indications.
Synthetic cannabinoid manufacturing system (IntegraSyn-style platform)
A platform-level manufacturing approach designed to produce bioidentical cannabinoids at pharmaceutical grade and scale as an alternative to plant extraction.
Pipeline of small-molecule therapeutics targeting CB1/CB2 pathways
Clinical- and preclinical-stage small-molecule programs focused on neurological (including Alzheimer’s disease), ophthalmic (dry age-related macular degeneration) and dermatological (epidermolysis bullosa, glaucoma) indications.
Synthetic cannabinoid manufacturing system (IntegraSyn-style platform)
A platform-level manufacturing approach designed to produce bioidentical cannabinoids at pharmaceutical grade and scale as an alternative to plant extraction.
Services
Production and commercial sale of pharmaceutical-grade, THC-free rare cannabinoids for use as raw ingredients in health and therapeutic products.
Production and commercial sale of pharmaceutical-grade, THC-free rare cannabinoids for use as raw ingredients in health and therapeutic products.
Expertise Areas
- Clinical trial management and execution
- Cannabinoid synthesis and manufacturing
- Preclinical pharmacology for neurodegenerative and ophthalmic diseases
- Dermatological formulation development
Key Technologies
- CB1/CB2-targeted small-molecule therapeutics
- Synthetic cannabinoid manufacturing platform
- Microbial metabolic engineering
- Enzyme-based biosynthetic pathways
News & Updates
Company representative presented preclinical data on an Alzheimer’s disease candidate in a scientific poster at AAIC 2025.
Abstract and oral presentation describing Phase 2 clinical study results for a topical cannabinol cream demonstrating anti-itch activity in patients with epidermolysis bullosa.
Management participated in multiple investor and industry conferences including H.C. Wainwright annual conferences, Emerging Growth Conference, and J.P. Morgan Healthcare Conference to present program progress and business updates.
Company representative presented preclinical data on an Alzheimer’s disease candidate in a scientific poster at AAIC 2025.
Abstract and oral presentation describing Phase 2 clinical study results for a topical cannabinol cream demonstrating anti-itch activity in patients with epidermolysis bullosa.
Management participated in multiple investor and industry conferences including H.C. Wainwright annual conferences, Emerging Growth Conference, and J.P. Morgan Healthcare Conference to present program progress and business updates.